(secondQuint)A Extension Study of Udenafil in Adolescents.

 This will be an open-label extension study.

 All enrolled subjects will be provided with udenafil for the duration of the study.

 Subjects completing the Phase III FUEL study will be eligible for recruitment.

 Additional subjects will be recruited as needed to ensure a minimum of 300 total subjects enroll.

 Safety, pharmacodynamic and quality of life data will be collected and analyzed.

.

 A Extension Study of Udenafil in Adolescents@highlight

This study is a 12-month (52 week) safety extension study to supplement the FUEL Phase III clinical trial to provide safety information regarding the long-term use of udenafil in adolescents with single ventricle congenital heart disease.

